Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish group ...
It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage ...
John F. Kennedy, with cane in the Pacific, 1943, would later downplay his PT-109 role: "It was involuntary," he quipped. "They sank my boat." Ted Robinson John F. Kennedy—elected 50 years ago this ...
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results